1. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
by Pau Abrisqueta, Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants, Lourdes Escoda, Xavier Calvo, Sabela Bobillo, José Bruno Montoro, Emili Montserrat, and Francesc Bosch
Blood
Volume 122(24):
December 5, 2013
©2013 by American Society of Hematology

2. Consort diagram. Consort diagram.
Pau Abrisqueta et al. Blood 2013;122:
©2013 by American Society of Hematology

3. OS and PFS in the R-FCM trial.
OS and PFS in the R-FCM trial. (A) OS and PFS in the whole series. (B) OS and PFS in patients entering the rituximab maintenance-study phase. (C) PFS in patients grouped by MRD levels assessed in PB after induction evaluation. (D) PFS according to MRD levels in BM after induction evaluation. (E) PFS combining the degree of response and the MRD status in PB.
Pau Abrisqueta et al. Blood 2013;122:
©2013 by American Society of Hematology

4. Infectious episodes observed in the R-FCM trial during the maintenance phase.
Infectious episodes observed in the R-FCM trial during the maintenance phase. (A) Percentage of grade 3 to 4 infectious episodes. (B) Grade 3 to 4 neutropenia episodes by cycle of treatment.
Pau Abrisqueta et al. Blood 2013;122:
©2013 by American Society of Hematology

5. Comparison of the R-FCM with the previous FCM trial
Comparison of the R-FCM with the previous FCM trial.34 (A) Probability of conversion from MRD-negative to MRD-positive in the R-FCM + R and FCM cohorts.
Comparison of the R-FCM with the previous FCM trial.34 (A) Probability of conversion from MRD-negative to MRD-positive in the R-FCM + R and FCM cohorts. (B) TNT in patients who achieved a CR MRD-negative after initial treatment with R-FCM or FCM. (C) TNT in patients who achieved a CR MRD-positive after R-FCM or FCM. (D) TNT in patients who achieved a PR after R-FCM or FCM. (E) MRD kinetics of 11 representative patients of the R-FCM + R cohort. Dotted line box represents period under rituximab maintenance. (F) MRD kinetics of 11 representative patients of the FCM cohort.
Pau Abrisqueta et al. Blood 2013;122:
©2013 by American Society of Hematology